CD274 and neoplasm: Researchers have observed that treatment with anti-PD-L1 antibody ibrutinib (a covalent inhibitor of Bruton’s tyrosine kinase) suppresses tumor growth in mouse models of triple-negative breast cancer (TNBC) [23].